Friday 6 November 2026 Export CAI’s income statement to Excel — free account

Caris Life Sciences,�Inc.

Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.

Revenue: +27.0%
EPS: −40.3%
Free cash flow: −140.2%
Total debt: +4.46%

Quarter to September 2026, against a year earlier

Insider buying

25.11 0.92 −3.53%

Follow CAI

Alert me

Market cap: $7.4B
P/E: 77.7×
Fwd P/E: 254×
Dividend yield: —
F-score: n/a
Altman Z: 3.55
Beneish M: −2.71
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Caris Life Sciences,�Inc. 10-Q filed Aug 5, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed Aug 5, 2026 · accepted 5:00 PM ET · Document on sec.gov · Filing index

Red flags

Inventory outpacing revenue Aug 5, 2026
Inventory grew 204.8% while revenue grew 45.4% year over year

10-Q filed Aug 5, 2026 · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 12, 2025: 29 added · 47 removed · 48 modified; 7 with only figures updated

Caris Life Sciences,�Inc. 10-Q filed Aug 5, 2026

Red flags

What changed

Stockrow Weekly